Breakthrough Meningitis Vaccine Developed for Africa at Affordable Price

          A new conjugate vaccine against meningococcus A costing only $0.5 (£0.3; €0.4) a dose that has been developed for use in Africa is about to be introduced for the first time in a national vaccination programme in Burkina Faso, researchers announced.

• The campaign to vaccinate all children and young adults from the ages of 1 to 29 years with the vaccine, MenAfriVac, will begin in Burkina Faso on 6 December. Niger and Mali will follow with similar vaccination campaigns.

Countries in the so called meningitis belt in sub-Saharan Africa—from Senegal in the west to Somalia in the east—have had regular epidemics of meningococcal meningitis for the past century. Almost all of the major outbreaks are caused by group A Neisseria menigitidis.

Sources:

http://www.who.int/mediacentre/factsheets/fs141/en/

http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001633

http://www.doctorswithoutborders.org